Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), January 13, 2026 – GENFIT (Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the half-year report of the liquidity contract with Crédit Industriel et Commercial.
Under the liquidity contract GENFIT has with Crédit Industriel et Commercial, the following resources appeared on the liquidity account as of December 31, 2025:
16,177 shares€1 109 238.29 During the second half of 2025, total trading was:On the buy side: 1,330,219 shares for a total amount of €4,996,375.72On the sell side: 1,515,142 shares for a total amount of €5,707,129.34 During this same period, the number of trades were:On the buy side: 2,585On the sell side: 2,576 As a reminder, upon signing of the contract, the following resources appeared on the liquidity account:27,911 shares€769,849.43 END
ABOUT GENFIT
GENFIT is a biopharmaceutical company committed to improving the lives of patients with rare, life-threatening liver diseases whose medical needs remain largely unmet. GENFIT is a pioneer in liver disease research and development with a rich history and a solid scientific heritage spanning more than two decades.
Today, GENFIT focuses on Acute on-chronic Liver Failure (ACLF) and associated conditions such as acute decompensation (AD) and hepatic encephalopathy (HE). It develops therapeutic assets which have complementary mechanisms of action, selected to address key pathophysiological pathways. GENFIT also targets other serious diseases, such as cholangiocarcinoma (CCA), urea cycle disorders (UCD) and organic acidemia (OA). Its R&D portfolio, covering several stages of development, ensures a constant news flow.
GENFIT’s expertise in developing high-potential molecules – from early to advanced pre-commercialization stages – culminated in 2024 with the accelerated approval of Iqirvo® (elafibranor) by the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA) and the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom for the treatment of Primary Biliary Cholangitis (PBC). Iqirvo® is now marketed in several countries.1
Beyond therapies, GENFIT also has a diagnostic franchise including NIS2+® for the detection of Metabolic dysfunction-associated steatohepatitis (MASH, formerly known as NASH for non-alcoholic steatohepatitis).
GENFIT, a BCorp™ certified company since 2025, is headquartered in Lille, France and has offices in Paris (France), Zurich (Switzerland) and Cambridge, MA (USA). The Company is listed on the Euronext regulated market in Paris, Compartment B (Euronext: GNFT). In 2021, Ipsen became one of GENFIT’s largest shareholders, acquiring an 8% stake in the Company’s capital. www.genfit.com
FORWARD LOOKING STATEMENTS
This press release contains certain forward-looking statements, including those within the meaning of the Private Securities Litigation Reform Act of 1995, in relation to GENFIT’s research and development programs. The use of certain words, such as “believe”, “potential”, “expect”, “target”, “may”, “will”, “should”, “could”, “if” and similar expressions, is intended to identify forward-looking statements. Although the Company believes its expectations are based on the current expectations and reasonable assumptions of the Company’s management, these forward-looking statements are subject to numerous known and unknown risks and uncertainties, which could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking statements. These risks and uncertainties include, among others, the uncertainties inherent in research and development, including in relation to non-clinical and pre-clinical programs, reproducibility of preclinical results, the translation of animal model data to human biology, in relation to safety of drug candidates, cost of, progression of, and results from, our ongoing and planned clinical trials, patient recruitment, review and approvals by regulatory authorities in the United States, Europe and worldwide, of our drug and diagnostic candidates, pricing, approval and commercial success of elafibranor in the relevant jurisdictions, exchange rate fluctuations, and our continued ability to raise capital to fund our development, as well as those risks and uncertainties discussed or identified in the Company’s public filings with the AMF, including those listed in Chapter 2 “Risk Factors and Internal Control” of the Company’s 2024 Universal Registration Document filed on April 29, 2025 (no. 25-0331) with the Autorité des marchés financiers (“AMF”), which is available on GENFIT’s website (www.genfit.fr) and the AMF’s website (bdif.amf-france.org), and those discussed in the public documents and reports filed with the U.S. Securities and Exchange Commission (“SEC”), including the Company’s 2024 Annual Report on Form 20-F filed with the SEC on April 29, 2025 and subsequent filings and reports filed with the AMF or SEC or otherwise made public, by the Company. In addition, even if the results, performance, financial position and liquidity of the Company and the development of the industry in which it operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. These forward-looking statements speak only as of the date of publication of this press release. Other than as required by applicable law, the Company does not undertake any obligation to update or revise any forward-looking information or statements, whether as a result of new information, future events or otherwise.
CONTACTS
GENFIT | Investors
Tel: +33 3 2016 4000 | investors@genfit.com
GENFIT | Media
Stephanie Boyer – Press relations | Tel: +333 2016 4000 | stephanie.boyer@genfit.com
GENFIT | 885 Avenue Eugène Avinée, 59120 Loos – FRANCE | +333 2016 4000 | www.genfit.com
APPENDIX
H2 2025
Buy sideSell sideDateNumber of executionsNumber of sharesTraded amounts in EURNumber of executionsNumber of sharesTraded amounts in EURTOTAL2 5851 330 2194 996 375,722 5761 515 1425 707 129,3401/07/202522680022 297,6818881629 006,2302/07/202515665122 021,3321793626 417,7503/07/2025512639988 188,24261957365 627,6804/07/2025211308143 260,83181865361 921,6207/07/2025332113669 530,4711642321 251,2008/07/202513632120 545,9714870528 339,7409/07/202513450014 704,02201175138 451,6210/07/2025301133437 338,73322177971 993,9711/07/2025361106836 264,0815472015 514,2214/07/2025291067434 589,20361110136 073,8115/07/2025251270143 420,275132982111 612,0816/07/2025141180939 684,50311607554 363,0817/07/202516636421 343,3317829327 858,8418/07/2025271203040 934,72371456749 740,3321/07/2025422005167 104,4817874829 340,1822/07/2025261430647 190,2016875628 927,9923/07/2025331570153 628,344833532113 250,3124/07/2025452400183 872,455532930115 532,2725/07/20257972734 197,02131760162 197,0128/07/202512820229 743,81271401550 857,7729/07/2025241461653 176,52201159442 866,0330/07/2025141150140 588,6417812328 835,4331/07/202519930132 595,54151078838 101,3801/08/2025222200174 968,41382492984 488,6204/08/2025825168 464,9110831328 238,6005/08/2025113,37221318944 953,6506/08/2025201000233 589,52226,9207/08/2025515014 956,30231150138 540,5408/08/202510300110 009,3311400113 463,3211/08/202517500116 697,348400113 451,3612/08/20259467815 706,8510467815 774,3613/08/2025113,36271950167 503,3014/08/2025518966 804,5015850130 669,5715/08/2025
Source: GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial
